Drug details

Ampyra (dalfampridine extended-release tablets)

type of Potassium Channel Blockers

Ampyra (dalfampridine) Extended-Release is a potassium channel blocker used to improve walking in patients with multiple sclerosis (MS).

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• numbness,
• seizure,
• burning pain,
• pain or burning when you urinate,
• tingly feeling,
• problems with balance, and
• relapse or worsening of MS symptoms

The following drugs are related to Ampyra, either as a replacement or used together:

• Lemtrada (alemtuzumab injection for intravenous infusion)
• Avonex (interferon beta-1a)
• Lyvispah (baclofen oral granules)
• Betaseron (interferon beta-1b)
• Copaxone (glatiramer acetate)
• Zinbryta (daclizumab for injection)
• Dantrium IV (dantrolene sodium for injection)
• Glatopa (glatiramer acetate injection)
• Rebif (interferon beta-1a)
• Kesimpta (ofatumumab injection)
• Novantrone (mitoxantrone for injection concentrate)
• Tysabri (natalizumab)
• Ocrevus (ocrelizumab injection)
• Zeposia (ozanimod capsules)
• Plegridy (peginterferon beta-1a injection for subcutaneous use)